Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 20/20 | 1.00 |
| ▸ | LGALS1 | P09382 | 8/20 | 0.75 |
| ▸ | LGALS8 | O00214 | 6/20 | 0.59 |
| ▸ | LGALS9 | O00182 | 5/20 | 0.53 |
| ▸ | LGALS2 | P05162 | 2/20 | 0.53 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.53 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23435225 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8LGALS9LGALS2 | |
| SCHEMBL17993073 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8LGALS9LGALS2 | |
| SCHEMBL19681090 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8LGALS9LGALS2 | |
| SCHEMBL23435260 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8LGALS9LGALS2 | |
| SCHEMBL19681042 | 1.00 | LGALS3 (1.00) | LGALS3LGALS1LGALS8LGALS9LGALS2 | |
| SCHEMBL16231593 | 0.87 | LGALS3 (0.91) | LGALS3LGALS1LGALS8LGALS9LGALS2 | |
| SCHEMBL16226874 | 0.87 | LGALS3 (0.91) | LGALS3LGALS1LGALS8LGALS9LGALS2 | |
| SCHEMBL16234116 | 0.87 | LGALS3 (0.91) | LGALS3LGALS1LGALS8LGALS9LGALS2 | |
| SCHEMBL23435226 | 0.83 | LGALS3 (0.72) | LGALS3LGALS1LGALS8LGALS9LGALS2 | |
| SCHEMBL16234130 | 0.79 | LGALS3 (0.73) | LGALS3LGALS1LGALS8LGALS9LGALS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377464-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2022-07-05 | — | — | US | claimed |
| EP-3828191-A2 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2021-06-02 | — | — | EP | claimed |
| US-20200407391-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2020-12-31 | — | — | US | claimed |
| US-10774102-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2020-09-15 | — | — | US | claimed |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2017-12-07 | — | — | US | claimed |
| US-11919921-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2024-03-05 | — | — | US | disclosed |
| US-11377464-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2022-07-05 | — | — | US | disclosed |
| CN-113621005-A | alpha-D-galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-107406478-B | alpha-D-galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-3828191-A2 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2021-06-02 | — | — | EP | disclosed |
| EP-3250581-B1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2021-01-20 | — | — | EP | disclosed |
| US-20200407391-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2020-12-31 | — | — | US | disclosed |
| US-10774102-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2020-09-15 | — | — | US | disclosed |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407391-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885LGALS8 6/4885 |
| US-11377464-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | LGALS3 1/4885LGALS1 2/4885LGALS8 6/4885 |
| US-11919921-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | LGALS3 1/4885LGALS1 2/4885LGALS8 6/4885 |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS3, LGALS1, LGALS2 | LGALS3 1/4885LGALS1 2/4885LGALS8 6/4885 |
| US-10774102-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | LGALS3 1/4885LGALS1 2/4885LGALS8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.